Nothing Special   »   [go: up one dir, main page]

MX2015012549A - Formulaciones de conjugado anticuerpo anti-egfr-farmaco. - Google Patents

Formulaciones de conjugado anticuerpo anti-egfr-farmaco.

Info

Publication number
MX2015012549A
MX2015012549A MX2015012549A MX2015012549A MX2015012549A MX 2015012549 A MX2015012549 A MX 2015012549A MX 2015012549 A MX2015012549 A MX 2015012549A MX 2015012549 A MX2015012549 A MX 2015012549A MX 2015012549 A MX2015012549 A MX 2015012549A
Authority
MX
Mexico
Prior art keywords
egfr antibody
drug conjugate
antibody drug
conjugate formulations
formulations
Prior art date
Application number
MX2015012549A
Other languages
English (en)
Inventor
Markus Tschoepe
Katharina Kaleta
Vineet Kumar
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2015012549A publication Critical patent/MX2015012549A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención se refiere a una formulación estable que comprende un conjugado de anticuerpo anti-EGFR-Fármaco (CAF), que incluye un anticuerpo anti-EGFR, por ejemplo, el anticuerpo I, conjugado con auristatina, por ejemplo, MMAF, histidina, un azúcar, y un tensoactivo.
MX2015012549A 2013-03-15 2014-03-14 Formulaciones de conjugado anticuerpo anti-egfr-farmaco. MX2015012549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790490P 2013-03-15 2013-03-15
PCT/US2014/027868 WO2014143765A1 (en) 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations

Publications (1)

Publication Number Publication Date
MX2015012549A true MX2015012549A (es) 2016-06-21

Family

ID=50680154

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012549A MX2015012549A (es) 2013-03-15 2014-03-14 Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
MX2020000333A MX2020000333A (es) 2013-03-15 2015-09-11 Formulaciones de conjugado anticuerpo anti-egfr-farmaco.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020000333A MX2020000333A (es) 2013-03-15 2015-09-11 Formulaciones de conjugado anticuerpo anti-egfr-farmaco.

Country Status (28)

Country Link
US (2) US20140286969A1 (es)
EP (2) EP2968588B1 (es)
JP (4) JP6382935B2 (es)
KR (4) KR20220139443A (es)
CN (2) CN105163763B (es)
AU (4) AU2014228172B2 (es)
BR (1) BR112015023391A8 (es)
CA (1) CA2906130A1 (es)
CY (1) CY1121949T1 (es)
DK (1) DK2968588T3 (es)
ES (1) ES2727134T3 (es)
HK (2) HK1217644A1 (es)
HR (1) HRP20190672T1 (es)
HU (1) HUE044071T2 (es)
IL (2) IL241009A0 (es)
LT (1) LT2968588T (es)
ME (1) ME03457B (es)
MX (2) MX2015012549A (es)
NZ (1) NZ630826A (es)
PL (1) PL2968588T3 (es)
PT (1) PT2968588T (es)
RS (1) RS58666B1 (es)
RU (2) RU2015144287A (es)
SG (2) SG10201707633VA (es)
SI (1) SI2968588T1 (es)
TR (1) TR201905313T4 (es)
TW (3) TWI689313B (es)
WO (1) WO2014143765A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
RU2013138177A (ru) 2011-01-24 2015-03-10 Йм Биосайнсис Инк. Антитела, действующие селективно на клетки с повышенной плотностью мишени рецептор эпидермального фактора роста (egfr)
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CR20210097A (es) 2014-03-21 2022-04-27 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
WO2016065456A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
US10195175B2 (en) * 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
WO2017051254A1 (en) * 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
KR20180077300A (ko) 2015-11-25 2018-07-06 주식회사 레고켐 바이오사이언스 펩타이드 그룹을 포함하는 접합체 및 이와 관련된 제조방법
KR20180079452A (ko) 2015-11-25 2018-07-10 주식회사 레고켐 바이오사이언스 자기-희생기를 포함하는 접합체 및 이의 제조방법
US11173214B2 (en) 2015-11-25 2021-11-16 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
RU2740996C2 (ru) * 2016-05-17 2021-01-22 Эббви Байотерапьютикс Инк. КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3468616A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-egfr antibody drug conjugates
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
AU2018280485A1 (en) * 2017-06-06 2020-01-30 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising c-Met antibody-drug conjugate and use thereof
CN118767159A (zh) * 2017-08-23 2024-10-15 第一三共株式会社 抗体-药物缀合物制剂及其冻干
EP3677589A4 (en) 2017-08-31 2021-04-21 Daiichi Sankyo Company, Limited IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
CN112601555A (zh) 2018-05-09 2021-04-02 乐高化学生物科学股份有限公司 与抗cd19抗体药物结合物相关的组合物和方法
KR20210091698A (ko) * 2018-09-20 2021-07-22 파세비오 파마수티컬스 인코포레이티드 티카그렐러 활성을 반전시키는 방법
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
UA128098C2 (uk) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Водна фармацевтична композиція антитіла проти il-17a
AU2020231509A1 (en) 2019-03-04 2021-08-19 Amgen Inc. In vivo reversibility of high molecular weight species
WO2020192693A1 (zh) * 2019-03-26 2020-10-01 荣昌生物制药(烟台)股份有限公司 抗Her2抗体药物偶联物药物制剂
WO2020233534A1 (zh) * 2019-05-17 2020-11-26 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
CN112516090B (zh) * 2019-09-18 2023-06-20 上海复旦张江生物医药股份有限公司 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
KR20220157998A (ko) * 2020-03-25 2022-11-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항체 약물 접합체를 포함하는 약학적 조성물 및 이의 용도
US20230181499A1 (en) * 2020-04-10 2023-06-15 Lantern Pharma Inc. Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer
KR102683876B1 (ko) * 2020-11-11 2024-07-11 가톨릭대학교 산학협력단 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트
EP4245319A1 (en) * 2020-11-11 2023-09-20 The Catholic University of Korea Industry-Academic Cooperation Foundation Antibody-based conjugate for enhancing therapeutic effect of targeted therapeutic agent
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN115300623B (zh) * 2021-05-08 2024-06-21 盛禾(中国)生物制药有限公司 抗egfr融合蛋白或其抗原结合片段的组合物及其用途
US20230027739A1 (en) 2021-05-10 2023-01-26 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
CN115721732A (zh) * 2021-08-27 2023-03-03 上海复旦张江生物医药股份有限公司 抗体偶联药物的药物组合物、制剂及其制备方法、用途
EP4429654A1 (en) 2021-11-09 2024-09-18 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
WO2023240223A2 (en) * 2022-06-10 2023-12-14 Acelyrin, Inc. Anti-igf-1r antibody compositions
TW202412856A (zh) * 2022-06-15 2024-04-01 大陸商上海翰森生物醫藥科技有限公司 一種含抗體藥物偶聯物的醫藥組成物及其用途
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2166368T3 (es) * 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
EP0973540B1 (en) 1997-02-25 2005-11-02 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US20050023292A1 (en) * 2003-02-14 2005-02-03 Rubbermaid Commercial Products Llc Liquid dispenser
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
EP1725586B1 (en) 2004-03-02 2015-01-14 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1740954B1 (en) * 2004-04-07 2015-08-19 Genentech, Inc. Mass spectrometry of antibody conjugates
EP3088004B1 (en) * 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2616005C (en) 2005-07-18 2015-09-22 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
JP2009509918A (ja) 2005-08-05 2009-03-12 シンタルガ・ビーブイ トリアゾール含有放出可能なリンカー、これらの共役体、および製造方法
US8586714B2 (en) * 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CN102892430A (zh) * 2010-03-17 2013-01-23 雅培研究有限公司 抗神经生长因子(ngf)抗体组合物
US9044460B2 (en) * 2010-05-04 2015-06-02 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
SG10201800313UA (en) * 2013-03-15 2018-02-27 Abbvie Inc Antibody drug conjugate (adc) purification
MY182415A (en) * 2014-02-18 2021-01-25 Illumina Inc Methods and compositions for dna profiling

Also Published As

Publication number Publication date
AU2014228172A1 (en) 2015-09-24
HUE044071T2 (hu) 2019-09-30
JP2022126754A (ja) 2022-08-30
JP2020143152A (ja) 2020-09-10
US20140286969A1 (en) 2014-09-25
TR201905313T4 (tr) 2019-05-21
EP2968588B1 (en) 2019-01-09
CN110433139A (zh) 2019-11-12
RU2015144287A3 (es) 2018-03-19
ES2727134T3 (es) 2019-10-14
AU2020277164A1 (en) 2020-12-24
ME03457B (me) 2020-01-20
PT2968588T (pt) 2019-05-08
LT2968588T (lt) 2019-05-10
JP2016515511A (ja) 2016-05-30
AU2018267662A1 (en) 2018-12-13
KR102305226B1 (ko) 2021-09-29
SI2968588T1 (sl) 2019-05-31
NZ732015A (en) 2022-01-28
BR112015023391A2 (pt) 2017-11-28
EP3517132A1 (en) 2019-07-31
DK2968588T3 (en) 2019-04-23
NZ630826A (en) 2017-06-30
WO2014143765A8 (en) 2015-09-11
US20200282072A1 (en) 2020-09-10
KR20220139443A (ko) 2022-10-14
TWI689313B (zh) 2020-04-01
KR20150131366A (ko) 2015-11-24
KR20210118238A (ko) 2021-09-29
TW201519903A (zh) 2015-06-01
JP6382935B2 (ja) 2018-08-29
TW201945032A (zh) 2019-12-01
PL2968588T3 (pl) 2019-08-30
TW202146054A (zh) 2021-12-16
AU2014228172B2 (en) 2018-12-06
EP2968588A1 (en) 2016-01-20
SG11201507430RA (en) 2015-10-29
CN105163763B (zh) 2019-07-02
RU2020125266A (ru) 2020-09-24
JP2018184468A (ja) 2018-11-22
IL241009A0 (en) 2015-11-30
IL274881A (en) 2020-07-30
MX2020000333A (es) 2020-07-13
CN105163763A (zh) 2015-12-16
BR112015023391A8 (pt) 2018-01-30
HRP20190672T1 (hr) 2019-08-23
HK1219044A1 (zh) 2017-03-24
RS58666B1 (sr) 2019-06-28
CA2906130A1 (en) 2014-09-18
AU2023200432A1 (en) 2023-03-02
RU2015144287A (ru) 2017-04-24
KR20220041957A (ko) 2022-04-01
WO2014143765A1 (en) 2014-09-18
CY1121949T1 (el) 2020-10-14
HK1217644A1 (zh) 2017-01-20
SG10201707633VA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
MX2020000333A (es) Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
PH12019501931A1 (en) Anti-pdl1 antibody formulations
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
WO2017062271A3 (en) Antibody drug conjugate for anti-inflammatory applications
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
EP3638248A4 (en) CONJUGATES OF PHARMACEUTICAL INGREDIENTS
CL2015002330A1 (es) Análogo de insulina novedoso y su uso.
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
EP4420729A3 (en) Antibody-drug conjugate formulation
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MY185802A (en) Antibody formulation
MX2016005395A (es) Formulacion estable de insulina glulisina.
EP4335851A3 (en) Pharmaceutical formulations and methods of use thereof
EP3723811A4 (en) TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
MX2018008300A (es) Formulacion para anticuerpo y conjugado de farmaco del mismo.
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
WO2013170086A3 (en) Formulations for the delivery of active ingredients
MX345263B (es) Formulación de pexiganan estable.
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
EP3719031A4 (en) PROCESS FOR CONJUGATION OF ANTIBODIES AND PHYSIOLOGICALLY ACTIVE SUBSTANCES
PH12018502139A1 (en) Phosphaplatin liquid formulations
EP3624828A4 (en) PHARMACEUTICAL FORMULATION WITH INCRETIN-INSULIN CONJUGATES
EP3700533A4 (en) SSTR-TARGETING CONJUGATES AND FORMULATIONS THEREOF
TR201714964A2 (tr) Efervesan tablet formülasyonları.
UA86132U (ru) Фармацевтическая композиция для лечения эндо- и эктопаразитозов

Legal Events

Date Code Title Description
FG Grant or registration